Tissue Therapeutics , Signs 2nd cGMP Manufacturing Contract With QSV Biologics, Ltd., For Synthetic Vitronectin And Chimeric VitroGro(R)-1
Published: Aug 23, 2006
QSV Biologics (QSV), Ltd. Edmonton, Canada, announced today that they have signed a 2nd contract with Tissue Therapies Limited (ASX: TIS) of Brisbane, Australia. This contract is for the cGMP manufacture of clinical quantities of synthetic Vitronectin (one of the components of the VitroGro(R) platform for accelerated wound healing) and a single protein, chimeric form of VitroGro(R), called VitroGro(R)-1. The VitroGro(R)-1 protein combines the active regions of the multiple protein components of VitroGro(R). These are some of the essential materials that Tissue Therapies will use in preclinical and clinical trials early next year. Under the agreement, QSV will be responsible for technology transfer and cGMP production in QSV's licensed manufacturing facility. Terms of the final manufacturing contract remain confidential.